• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
      • shARC Platform
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

Celyad Oncology Announces Leadership Updates

June 24, 2022
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

May 31, 2022
READ THE PRESS RELEASE

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022
READ THE PRESS RELEASE

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

May 5, 2022
READ THE PRESS RELEASE

Letter to Shareholders – March 2022

March 25, 2022
READ THE PRESS RELEASE

Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

March 24, 2022
READ THE PRESS RELEASE

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

March 17, 2022
READ THE PRESS RELEASE

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

March 2, 2022
READ THE PRESS RELEASE

Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

February 28, 2022
READ THE PRESS RELEASE

Celyad Oncology Announces February 2022 Conference Schedule

January 31, 2022
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology @celyadsa ·
1 Jul

Introducing shARC - our new armored CAR franchise focused on the treatment of #solidtumors and hematological malignancies. Discover more about our platform on its new website page: https://buff.ly/3AeXDCa

Twitter 1542875935845793792
Celyad Oncology @celyadsa ·
29 Jun

Meet Michel Lussier, the new interim CEO of Celyad Oncology! Not only did Michel co-found the company, but he has been a member of the Board of Directors since 2007. Learn more about his background on our management page: https://buff.ly/3JePQVP

Twitter 1542115838609833986

View All

Stay informed about the latest news!

Sign up FOR our newsletter

Please enter a valid email address.
Submit

Thanks for subscribing! Please check your email for further instructions.

Something went wrong. Please check your entries and try again.

By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.

Footer

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use